Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Xing, JunBhuria, Vikas
Bui, Khac Cuong
Nguyen, Mai Ly Thi
Hu, Zexi
Hsieh, Chih-Jen
Wittstein, Kathrin
Stadler, Marc
Wilkens, Ludwig
Li, Jun
Kalesse, Markus
Bozko, Przemyslaw
Plentz, Ruben R
Issue Date
2020-03-06
Metadata
Show full item recordAbstract
The efficacy of haprolid was evaluated in human HCC cell lines (Huh-7, Hep3B and HepG2) and xenograft tumors (NMRI-Foxn1nu mice with injection of Hep3B cells). Cytotoxic activity of haprolid was determined by the WST-1 and crystal violet assay. Wound healing, transwell and tumorsphere assays were performed to investigate migration and invasion of HCC cells. Apoptosis and cell-cycle distribution were measured by flow cytometry. The effects of haprolid on the Rb/E2F and Akt/mTOR pathway were examined by immunoblotting and immunohistochemistry.Citation
Cancers (Basel). 2020 Mar 6;12(3). pii: cancers12030615. doi: 10.3390/cancers12030615.Affiliation
HZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.Publisher
MDPIJournal
CancersPubMed ID
32155915Type
ArticleLanguage
enISSN
2072-6694ae974a485f413a2113503eed53cd6c53
10.3390/cancers12030615
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International